Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium

PHASE2CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

November 16, 2009

Primary Completion Date

September 13, 2012

Study Completion Date

August 21, 2013

Conditions
Breast CancerHypercalcemia of MalignancyColon CancerEndocrine CancerHead and Neck CancerKidney CancerLung CancerLymphomaMetastatic CancerMultiple MyelomaParathyroid NeoplasmsRenal CancerThyroid CancerHodgkin's LymphomaNon-Hodgkin's LymphomaNon-Small Cell Lung Cancer
Interventions
DRUG

denosumab

120 mg subcutaneously (SC) every 4 weeks with a loading dose of 120 mg SC on study days 8 and 15.

Trial Locations (24)

10065

Research Site, New York

10467

Research Site, The Bronx

13210

Research Site, Syracuse

20162

Research Site, Milan

21801

Research Site, Salisbury

27534

Research Site, Goldsboro

27710

Research Site, Durham

34298

Research Site, Montpellier

35128

Research Site, Padua

40138

Research Site, Bologna

44035

Research Site, Nantes

48124

Research Site, Dearborn

48236

Research Site, Detroit

50139

Research Site, Florence

68114

Research Site, Omaha

77030

Research Site, Houston

87042

Research Site, Limoges

92024

Research Site, Encinitas

94805

Research Site, Villejuif

06520

Research Site, New Haven

G1S 4L8

Research Site, Québec

Research Site, Québec

00128

Research Site, Roma

01-809

Research Site, Warsaw

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY

NCT00896454 - Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium | Biotech Hunter | Biotech Hunter